{"product_id":"omi-vrio-analysis","title":"Owens \u0026 Minor, Inc. (OMI): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Owens \u0026amp; Minor, Inc. (OMI) truly built for sustained success? This VRIO analysis cuts straight to the core, dissecting the firm's resources based on their Value, Rarity, Inimitability, and Organization to uncover the true source of its competitive advantage - or lack thereof. Dive in below to see the definitive verdict on whether Owens \u0026amp; Minor, Inc. (OMI)'s assets translate into lasting market dominance.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eOwens \u0026amp; Minor, Inc. (OMI) - VRIO Analysis: \u003cstrong\u003e1. Nationwide Direct-to-Patient (D2P) Logistics Platform\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at Owens \u0026amp; Minor’s core bet post-divestiture: making the Patient Direct segment the sole focus. This platform, significantly bolstered by the Apria acquisition, is designed to capture the higher, more stable margins in home-based care for chronic conditions.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: Capturing Higher-Margin Care\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe D2P platform is valuable because it targets chronic condition management at home, which offers better margins than the divested institutional distribution business. For instance, in Q1 2025, this segment saw revenue growth of \u003cstrong\u003e5.7%\u003c\/strong\u003e to \u003cstrong\u003e$674 million\u003c\/strong\u003e and an Adjusted EBITDA increase of \u003cstrong\u003e17%\u003c\/strong\u003e to \u003cstrong\u003e$98 million\u003c\/strong\u003e. The strategic focus is clear: dedicate resources to this more profitable area.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: Scale in Home Healthcare Logistics\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eA truly nationwide D2P network in healthcare logistics is quite rare; many competitors only have regional strengths. The combination of OMI’s existing capabilities with Apria’s scale means the combined entity has access to over \u003cstrong\u003e90 percent\u003c\/strong\u003e of insured healthcare customers in the U.S. That kind of footprint is hard to replicate quickly.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: High Barrier to Entry\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHonestly, building out this physical footprint and securing the necessary payor contracts to match this scale takes many years and significant capital. The sheer logistics network required to service patients directly across the entire country is a massive undertaking. It’s not something a startup can just decide to do next Tuesday.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: Unified Strategic Execution\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe organization is now defintely strong because the strategic pivot is complete: the sale of the Products \u0026amp; Healthcare Services (P\u0026amp;HS) segment for \u003cstrong\u003e$375 million\u003c\/strong\u003e cash plus equity is designed specifically to exploit this D2P platform for growth. Management is unified around this model, aiming to reduce leverage from \u003cstrong\u003e3.98x\u003c\/strong\u003e to below \u003cstrong\u003e3x\u003c\/strong\u003e by 2026 using the proceeds.\u003c\/p\u003e\n\n\u003cp\u003eHere’s a quick look at the forward-looking numbers for this core business:\u003c\/p\u003e\n\u003ctable border=\"1\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric (Continuing Operations)\u003c\/th\u003e\n\u003cth\u003eQ2 2025 Actual\u003c\/th\u003e\n\u003cth\u003e2025 Full-Year Guidance Range\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (Continuing Ops)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$681.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$2.76 billion\u003c\/strong\u003e to \u003cstrong\u003e$2.82 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$96.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$376 million\u003c\/strong\u003e to \u003cstrong\u003e$382 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted Operating Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8.34%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTargeting \u003cstrong\u003e15%\u003c\/strong\u003e by 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Sustained Potential\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis scale, combined with the new, singular strategic focus, creates a significant barrier to entry in the pure-play home care space. The ability to dedicate all capital and management attention to scaling this platform is what drives the sustained advantage. What this estimate hides is the execution risk on integrating technology and automation, which CEO Edward Pesicka noted as a key investment area for scaling.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFocus on chronic conditions like diabetes and sleep apnea.\u003c\/li\u003e\n\u003cli\u003eLeveraging preferred provider agreements, like the one with Optum.\u003c\/li\u003e\n\u003cli\u003eStreamlined capital allocation post-P\u0026amp;HS sale.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: Draft the 2026 capital allocation plan prioritizing D2P technology spend by next Wednesday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eOwens \u0026amp; Minor, Inc. (OMI) - VRIO Analysis: \u003cstrong\u003e2. Strategic Partnership with Optum Health\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e This preferred provider agreement acts as a powerful, built-in customer acquisition channel, directing patient volume directly to Owens \u0026amp; Minor’s services, specifically through the Patient Direct business segment, which includes Apria and Byram and serves nearly \u003cstrong\u003ethree million patients\u003c\/strong\u003e each year.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. While large payor partnerships exist, a nationwide preferred status with a major entity like Optum Health is not common for a company of this new, focused scale.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Competitors can’t simply replicate this specific contractual relationship; it was earned through negotiation and demonstrated capability.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Effective. Management is clearly using this partnership as a cornerstone of its 2025 growth projections for the Patient Direct segment. The company reaffirmed its 2025 financial guidance for continuing operations (primarily Patient Direct) with a revenue range of between \u003cstrong\u003e$2.76 billion\u003c\/strong\u003e and \u003cstrong\u003e$2.82 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. While powerful now, the terms could change or competitors could secure similar deals over time, though it provides a strong near-term lift. The Patient Direct segment demonstrated strength in Q3 2024 with revenue of \u003cstrong\u003e$687 million\u003c\/strong\u003e, marking a \u003cstrong\u003e6%\u003c\/strong\u003e year-over-year increase.\u003c\/p\u003e\n\u003cp\u003eThe strategic focus on the Patient Direct segment, bolstered by the Optum Health agreement, is supported by the following recent and projected financial data:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003ePeriod\/Target\u003c\/th\u003e\n\u003cth\u003eAmount\/Value\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient Direct Segment Revenue\u003c\/td\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$687 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient Direct Segment Revenue Growth (YoY)\u003c\/td\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient Direct Segment Projected Revenue\u003c\/td\u003e\n\u003ctd\u003eFull Year 2025 Guidance\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.76 billion to $2.82 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected EBITDA Margin (Patient Direct)\u003c\/td\u003e\n\u003ctd\u003e2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e14.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients Served Annually (Patient Direct)\u003c\/td\u003e\n\u003ctd\u003eCurrent Scope\u003c\/td\u003e\n\u003ctd\u003eNearly \u003cstrong\u003ethree million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe partnership is intended to drive volume across key chronic and acute condition product categories:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDiabetes supplies\u003c\/li\u003e\n\u003cli\u003eSleep health\u003c\/li\u003e\n\u003cli\u003eRespiratory care\u003c\/li\u003e\n\u003cli\u003eWound care\u003c\/li\u003e\n\u003cli\u003eUrology and ostomy care\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eOwens \u0026amp; Minor, Inc. (OMI) - VRIO Analysis: \u003cstrong\u003e3. Core Competency in High-Growth Chronic Care Categories\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFocus on sleep, diabetes, wound care, and urology allows for deeper expertise, better inventory management, and higher revenue capture in growing therapy areas.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePatient Direct segment delivered 6% year-over-year revenue growth in Q1 2025, reaching $674 million.\u003c\/li\u003e\n\u003cli\u003ePatient Direct accounted for 25.6% of total revenue in Q1 2025, an increase from 24.4% in 2024.\u003c\/li\u003e\n\u003cli\u003eThe segment achieved high single-digit revenue growth in Sleep Supplies.\u003c\/li\u003e\n\u003cli\u003eThe segment achieved double-digit growth in Wound supplies, Ostomy, and Urology categories in Q1 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate. Many distributors touch these areas, but Owens \u0026amp; Minor’s deep focus, especially post-divestiture, creates specialized knowledge.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate. Competitors can shift focus, but the operational know-how and established patient relationships take time to match.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGood. The segment saw operating margins expand by \u003cstrong\u003e173 basis points in Q1 2025\u003c\/strong\u003e, showing they are effectively managing these specific product lines.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric (Q1 2025 vs Q1 2024)\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient Direct Operating Margin Expansion\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e173 basis points\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient Direct Operating Income Growth\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e31%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient Direct Operating Income Increase (Absolute)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient Direct Segment EBITDA Expansion\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMid-teen\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution, Selling and Administrative Expenses (% of Revenue)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e17.6%\u003c\/strong\u003e (down from 18.3% in Q1 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSustained. Deep specialization in chronic, recurring-need products creates stickier customer relationships than general medical supply distribution.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eOwens \u0026amp; Minor, Inc. (OMI) - VRIO Analysis: \u003cstrong\u003e4. Integrated Brand Portfolio (Apria®, Byram®)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e These established brand names carry inherent patient and provider trust, reducing friction in onboarding new patients to the D2P service.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eBrands include \u003cstrong\u003eApria®\u003c\/strong\u003e, \u003cstrong\u003eByram®\u003c\/strong\u003e, and \u003cstrong\u003eHALYARD\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe combination of these brands forms the backbone of the post-sale Patient Direct platform.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. While the P\u0026amp;HS segment is being sold, the core Patient Direct brands like Apria and Byram are well-known in their respective niches.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePatient Direct segment revenue grew \u003cstrong\u003e25.7%\u003c\/strong\u003e in Q1 2022 (including Apria's contribution from March 29, 2022).\u003c\/li\u003e\n\u003cli\u003ePatient Direct posted double-digit growth for four consecutive quarters as of Q2 2023.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Acquiring and successfully integrating well-regarded brands like Apria is a costly, complex, and time-consuming process.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eApria Equity Acquisition Value\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.45 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJanuary 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Apria Transaction Value\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.6 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMarch 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected FY 2025 Patient Direct Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.76 billion - $2.82 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFY 2025 Guidance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected Apria Revenue Synergies\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$80 million - $100 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLong-term estimate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ2 2023 Patient Direct Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$633 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Effective. The combination of these brands forms the backbone of the post-sale Patient Direct platform, which management expects to generate about \u003cstrong\u003e$2.76 billion to $2.82 billion\u003c\/strong\u003e in revenue for FY 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Brands can lose relevance, but the current recognition provides an immediate advantage over unbranded competitors.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe acquisition of Apria expanded the Patient Direct product portfolio to include home respiratory, obstructive sleep apnea, and negative pressure wound therapy, complementing Byram's strength in diabetes, ostomy, incontinence, and wound care.\u003c\/li\u003e\n\u003cli\u003eExpected long-term Adjusted EBITDA synergies from Apria integration are estimated at \u003cstrong\u003e$40 million - $50 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eOwens \u0026amp; Minor, Inc. (OMI) - VRIO Analysis: \u003cstrong\u003e5. Advanced Distribution Center Automation \u0026amp; Robotics\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe deployment of advanced technology in new facilities directly impacts operational metrics and customer service capabilities.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eFacility\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFacility Size\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e350,000 square-foot\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eWest Virginia Distribution Center\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCustomer Support\u003c\/td\u003e\n\u003ctd\u003eSupporting \u003cstrong\u003e25\u003c\/strong\u003e acute care hospitals\u003c\/td\u003e\n\u003ctd\u003eWVU Medicine network\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew Employment Goal\u003c\/td\u003e\n\u003ctd\u003eGoal of \u003cstrong\u003e100\u003c\/strong\u003e new team members\u003c\/td\u003e\n\u003ctd\u003eWest Virginia DC ramp-up\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperational Start Year\u003c\/td\u003e\n\u003ctd\u003eCapabilities operational starting in \u003cstrong\u003e2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eWest Virginia and South Dakota DCs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe specific combination of advanced robotics and AR integration is leading-edge for the sector, although automation is generally present.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTechnology Deployed: Advanced automation and robotics in West Virginia DC; Augmented Reality (AR) system in South Dakota DC.\u003c\/li\u003e\n\u003cli\u003eIndustry Capex Context (2024 Average Projected): \u003cstrong\u003e$2.16 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eIndustry Capex Context (2024 Median Projected): \u003cstrong\u003e$425,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe required investment level and specialized integration expertise create barriers to immediate replication.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eCost\/Expertise Factor\u003c\/th\u003e\n\u003cth\u003eAssociated Figure\u003c\/th\u003e\n\u003cth\u003eRelevance\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProject Cost Estimate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$50 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eInitial estimate for the West Virginia medical warehouse project\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEngineering Requirement\u003c\/td\u003e\n\u003ctd\u003eRequires specialized engineering and integration expertise\u003c\/td\u003e\n\u003ctd\u003eInferred from advanced robotics\/AR deployment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Company Revenue (FY 2025 Guidance)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.85 billion to $11.15 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eContext for capital expenditure scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eInvestments are aligned with strategic goals to enhance efficiency within the core business segment.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSegment Served: Products \u0026amp; Healthcare Services (P\u0026amp;HS).\u003c\/li\u003e\n\u003cli\u003eEfficiency Impact Example (Prior Initiative): Identified over \u003cstrong\u003e$10 million\u003c\/strong\u003e of product to source through OMI channel, with an initial focus of \u003cstrong\u003e$5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ2 2025 Adjusted Operating Margin: \u003cstrong\u003e8.34%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal Customers Served: More than \u003cstrong\u003e4,000\u003c\/strong\u003e healthcare provider facilities worldwide.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFirst-mover advantage in deploying this specific technology stack in new facilities provides a temporary lead.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003cth\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ2 2025 Adjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$96.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMeasure of operating profitability\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDeployment Status\u003c\/td\u003e\n\u003ctd\u003eWest Virginia DC is \u003cstrong\u003enow open\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eHead start on robotics deployment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSouth Dakota DC Opening\u003c\/td\u003e\n\u003ctd\u003eSpring \u003cstrong\u003e2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eTimeline for AR system deployment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eOwens \u0026amp; Minor, Inc. (OMI) - VRIO Analysis: \u003cstrong\u003e6. Supply Chain Visibility \u0026amp; Analytics Capabilities\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Better data visibility helps predict demand, manage inventory risk, and improve resiliency - crucial in the often-volatile medical supply market.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low to Moderate. Many large players have analytics, but OMI specifically highlighted these investments as transformative for supply chain resiliency. Investments in technology, automation, and analytics capabilities are being rolled out at new distribution centers in West Virginia (now open) and South Dakota (opening spring 2025) to improve visibility for the Products \u0026amp; Healthcare Services (P\u0026amp;HS) segment. The P\u0026amp;HS segment has struggled with margins reported at \u003cstrong\u003esub-1%\u003c\/strong\u003e. The Patient Direct segment revenue grew 8% year-over-year in Q4 2023.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. The proprietary algorithms or specific data sets built over time are hard to copy, even if the software platforms are available. The focus on enhancing distribution capabilities and leveraging analytics is part of a strategic vision articulated in December 2023.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Developing. These capabilities were explicitly invested in to support the P\u0026amp;HS segment, so their full benefit to the standalone Patient Direct model is still being realized. The company is actively working to optimize the P\u0026amp;HS business while growing the Patient Direct platform.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Analytics is a race; today’s edge can become tomorrow’s baseline requirement.\u003c\/p\u003e\n\u003cp\u003eContextual Financial Data:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\/Period\u003c\/td\u003e\n\u003ctd\u003eSource Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual Inventory Turnover\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e7.49\u003c\/strong\u003e (FYE 2024-12-31)\u003c\/td\u003e\n\u003ctd\u003eMeasure of inventory efficiency.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFull Year 2023 Consolidated Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.3 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOverall scale of operations.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 Revenue Guidance Midpoint\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.7 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eExpected scale for the year.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 2024 Gross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e20.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eImprovement of \u003cstrong\u003e79 basis points\u003c\/strong\u003e YoY.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient Direct Segment Projected 2025 Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.76–$2.82 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTarget for the core focus area.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eSpecific Operational\/Investment Highlights:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eInvestments in technology, automation, and analytics are geared toward driving greater efficiencies for the P\u0026amp;HS segment.\u003c\/li\u003e\n\u003cli\u003eThe company reduced total debt by \u003cstrong\u003e$244 million\u003c\/strong\u003e in 2024, capping a two-year total debt reduction of \u003cstrong\u003e$647 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ3 2024 saw a total debt reduction of \u003cstrong\u003e$198 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe Patient Direct segment is projected to achieve EBITDA margins expanding to \u003cstrong\u003e14.5%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eOwens \u0026amp; Minor, Inc. (OMI) - VRIO Analysis: \u003cstrong\u003e7. Management Expertise in Home-Based Care Market Focus\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The leadership team has demonstrated a clear, albeit disruptive, ability to pivot the entire company toward the higher-growth, chronic condition home care market.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. Successfully executing a major divestiture while maintaining guidance for the remaining core business is a rare feat of corporate management.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. This is tacit knowledge - the specific experience of navigating the regulatory and operational hurdles of this pivot is not easily transferred.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong. The entire 2025 guidance for continuing operations, projecting $376 million to $382 million in Adjusted EBITDA, rests on this focused execution.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Experienced leadership that successfully navigates a major strategic shift is a durable asset.\u003c\/p\u003e\n\u003cp\u003eThe strategic realignment is quantified by the financial projections for the focused Patient Direct segment and the terms of the divestiture of the Products \u0026amp; Healthcare Services (P\u0026amp;HS) segment.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Segment\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 Adjusted EBITDA Guidance (Continuing Operations)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$376 million\u003c\/strong\u003e to \u003cstrong\u003e$382 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eFocused Home-Based Care Business\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Proceeds from P\u0026amp;HS Divestiture\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$375 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSale to Platinum Equity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetained Equity Stake Post-Divestiture\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5 percent\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eP\u0026amp;HS Business\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreserved Tax Attributes Value\u003c\/td\u003e\n\u003ctd\u003eIn excess of \u003cstrong\u003e$150 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAssociated with Divestiture\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Revenue (Continuing Operations)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$697.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReflecting Focused Business Performance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Adjusted EBITDA (Continuing Operations)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$92 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReflecting Focused Business Performance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe focus on the home-based care market is supported by the performance metrics of the Patient Direct segment prior to the full transition:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePatient Direct revenue in Q1 2025 was \u003cstrong\u003e$674 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePatient Direct Adjusted EBITDA in Q1 2025 was \u003cstrong\u003e$98 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePatient Direct Adjusted EBITDA margin in Q1 2025 was \u003cstrong\u003e14.5%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe P\u0026amp;HS segment, which was divested, previously accounted for approximately \u003cstrong\u003e74%\u003c\/strong\u003e of total revenue, with its operating income declining by \u003cstrong\u003e90%\u003c\/strong\u003e in Q1 2025, illustrating the margin pressure the management successfully pivoted away from.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eOwens \u0026amp; Minor, Inc. (OMI) - VRIO Analysis: \u003cstrong\u003e8. Scale of Operations (Post-Divestiture Base)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eThe post-divestiture scale centers on the Patient Direct segment, which is the focus of the streamlined entity.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The remaining Patient Direct business provides significant leverage over suppliers and a large base for incremental growth, supported by its projected scale. Full-year 2025 revenue guidance for continuing operations is between \u003cstrong\u003e$2.76 billion\u003c\/strong\u003e and \u003cstrong\u003e$2.82 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. While smaller than the pre-divestiture entity, the Patient Direct business unit, with projected annual revenue near \u003cstrong\u003e$2.8 billion\u003c\/strong\u003e and an estimated workforce of \u003cstrong\u003e8,000+\u003c\/strong\u003e staff, remains a major national player in the home-based care market.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Achieving this level of scale organically within the Direct-to-Patient (D2P) space would necessitate years of significant acquisitions and sustained organic growth.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Good. This established national scale enables the organization to secure nationwide payor contracts and maintain comprehensive national service coverage. For example, management referenced an aggressive sales strategy including a preferred provider agreement with Optum.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Rating agencies have noted that the reduced scale and diversification post-sale inherently limit the company's leverage compared to its former, larger size.\u003c\/p\u003e\n\n\u003cp\u003eThe scale of the Patient Direct segment is quantified by recent and projected financial metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003ePeriod\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Full-Year Revenue\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$2.76 billion\u003c\/strong\u003e to \u003cstrong\u003e$2.82 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e2025 Guidance (Continuing Operations)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecent Quarterly Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$697 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecent Quarterly Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$681.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecent Quarterly Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$638 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ1 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$92 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$96.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e14.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ1 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe operational scale supports specific market capabilities:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Patient Direct segment delivered \u003cstrong\u003e5.7%\u003c\/strong\u003e revenue growth in Q1 2025.\u003c\/li\u003e\n\u003cli\u003eThe segment has been built over \u003cstrong\u003eeight years\u003c\/strong\u003e, leveraging acquisitions like Apria.\u003c\/li\u003e\n\u003cli\u003eThe company is focusing investments on technology and automation to allow it to \u003cstrong\u003equickly scale\u003c\/strong\u003e its business.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eOwens \u0026amp; Minor, Inc. (OMI) - VRIO Analysis: \u003cstrong\u003e9. Augmented Reality (AR) Supported Order Picking\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Implementing AR systems in new DCs, like the one in South Dakota opening in Spring 2025, directly improves picking accuracy and speed, cutting labor costs. OMI has a history of efficiency gains from technology, having previously rolled out Voice Picking Technology across 40 US distribution centers (DCs).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. Being an early adopter of AR for core warehouse functions in medical distribution is not widespread right now. OMI is rolling this out in a new state-of-the-art DC in South Dakota starting Spring 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. This requires specific IT integration, hardware investment, and retraining of the workforce, which is a significant hurdle for slower-moving competitors. The investment is part of broader technology, automation, and analytics capabilities.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Emerging. This is a new capability rolling out in 2025, so the full operational benefit is just starting to materialize. The company is focused on leveraging technology to shift operations from tactical to strategic.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It’s a technology adoption curve; others will catch up, but OMI has the first-mover advantage here.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFinance:\u003c\/strong\u003e Draft the 13-week cash flow projection incorporating the Q3 2025 actuals and the revised FY2025 guidance by Friday. The Q3 2025 actuals and FY2025 guidance provide the basis for near-term cash flow modeling.\u003c\/p\u003e\n\u003cp\u003eThe following table summarizes key financial metrics from Q3 2025 actuals against the reaffirmed FY2025 guidance range:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ3 2025 Actual\u003c\/th\u003e\n\u003cth\u003eFY 2025 Guidance Range\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$697.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$2.76 billion\u003c\/strong\u003e to \u003cstrong\u003e$2.82 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$92.20 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$376 million\u003c\/strong\u003e to \u003cstrong\u003e$382 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EPS\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$0.25\u003c\/strong\u003e per share\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$1.02\u003c\/strong\u003e to \u003cstrong\u003e$1.07\u003c\/strong\u003e per share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Capital Expenditures\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$205-$215 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eAdditional relevant financial and operational data points include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ3 2025 Revenue increase year-over-year: \u003cstrong\u003e1.5%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Adjusted EBITDA compared to Q3 2024: Declined from \u003cstrong\u003e$107.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Adjusted EPS compared to Q3 2024: Declined from \u003cstrong\u003e$0.36\u003c\/strong\u003e per share.\u003c\/li\u003e\n\u003cli\u003eYear-to-date (9 months) 2025 Revenue: \u003cstrong\u003e$2.053 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet Capital Expenditures projected for FY 2025: \u003cstrong\u003e$135-$145 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNumber of teammates worldwide: Over \u003cstrong\u003e20,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516223643797,"sku":"omi-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/omi-vrio-analysis.png?v=1740203408","url":"https:\/\/dcf-model.com\/products\/omi-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}